\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ bilateral\\ epididymal\\ masses\ \(0\)\
\-\ cystic\\ and\\ solid\\ heterogeneous\ \(1\)\
\-\ systemic\\ disease\ \(10\)\
\-\ inflammatory\\ vs\\.\\ neoplastic\ \(1\)\
\-\ \\â\\€\\¢\\ pancreatic\\ and\\ renal\\ masses\ \(0\)\
\-\ heterogeneous\ \(357\)\
\-\ systemic\\ disease\ \(10\)\
\-\ epididymal\\ cystadenomas\\,\\ von\\ hippel\\-lindau\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ von\\ hippel\\-lindau\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ von\\ hippel\\-lindau\\ syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ chromosome\\ 3\\ disease\ \(0\)\
\-\ 31\\ y\\.o\\.\\ man\\ with\\ bilateral\\ scrotal\\ masses\\.\\ \\ pmh\\ of\\ previous\\ resection\\ of\\ bilateral\\ adrenal\\ masses\\.\ \(0\)\
\-\ epididymal\\ cystadenomas\\ \\(eca\\)\\ are\\ uncommon\\ tumors\\ that\\,\\ even\\ as\\ sporadic\\ lesions\\,\\ are\\ associated\\ with\\ a\\ somatic\\ mutation\\ in\\ the\\ vhl\\ gene\\ on\\ chromosome\\ 3\\.\\ \\ in\\ von\\-hippel\\ lindau\\ disease\\ \\(vhl\\)\\ patients\\,\\ there\\ is\\ a\\ germ\\-line\\ mutation\\ in\\ the\\ vhl\\ gene\\,\\ affecting\\ every\\ cell\\ in\\ the\\ patient\\'s\\ body\\.\\ \\ the\\ presence\\ of\\ bilateral\\ epididymal\\ lesions\\ suggests\\ a\\ germline\\ systemic\\ mutation\\,\\ rather\\ than\\ a\\ local\\ somatic\\ mutation\\.\\ \\ of\\ course\\,\\ the\\ additional\\ findings\\ of\\ the\\ lesions\\ in\\ the\\ kidney\\ and\\ pancreas\\ provide\\ further\\ evidence\\ of\\ the\\ systemic\\ disease\\ \\-\\ von\\ hippel\\ lindau\\ disease\\.\ \(0\)\
\-\ vhl\\ was\\ originally\\ described\\ as\\ the\\ familial\\ association\\ of\\ multiple\\ vascular\\ \\"angiomas\\"\\ of\\ the\\ retina\\ \\(von\\ hippel\\ disease\\)\\ with\\ hemangioblastomas\\ \\(the\\ lindau\\ tumor\\)\\.\\ \\ however\\,\\ it\\ was\\ shortly\\ recognized\\ that\\ these\\ patients\\ had\\ a\\ more\\ complex\\ systemic\\ disease\\ with\\ lesions\\ affecting\\ the\\ solid\\ abdominal\\ organs\\ \\(kidney\\ and\\ pancreas\\)\\ with\\ cysts\\ and\\ both\\ benign\\ and\\ malignant\\ neoplasms\\.\\ \\ unlike\\ the\\ \\"classic\\"\\ phakomatoses\\,\\ vhl\\ is\\ not\\ associated\\ with\\ cutaneous\\ findings\\.\\ \\ vhl\\ is\\ autosomal\\ dominant\\,\\ without\\ racial\\ or\\ sexual\\ predilection\\.\\ \\ the\\ responsible\\ gene\\ has\\ been\\ identified\\ on\\ chromosome\\ 3p\\,\\ and\\ the\\ prevalence\\ is\\ estimated\\ at\\ about\\ 1\\/35\\,000\\ to\\ 1\\/50\\,000\\ people\\ in\\ the\\ united\\ states\\.\ \(0\)\
\-\ the\\ study\\ group\\ at\\ the\\ nih\\ has\\ suggested\\ subclassifying\\ vhl\\ into\\ 3\\ subtypes\\.\\ \\ the\\ most\\ frequent\\ is\\ type\\ i\\,\\ vhl\\ without\\ pheochromocytoma\\.\\ \\ these\\ patients\\ have\\ the\\ \\"classic\\"\\ features\\ of\\ renal\\ and\\ pancreatic\\ cysts\\,\\ and\\ a\\ high\\ risk\\ for\\ developing\\ renal\\ cell\\ carcinoma\\ \\(rcc\\)\\.\ \(0\)\
\-\ type\\ ii\\ is\\ vhl\\ with\\ pheochromocytoma\\,\\ and\\ it\\ is\\ further\\ divided\\ into\\ iia\\ and\\ iib\\.\\ \\ type\\ iia\\ has\\ pancreatic\\ islet\\ cell\\ tumors\\ \\(typically\\ without\\ cysts\\)\\ and\\ iib\\ has\\ both\\ renal\\ and\\ pancreatic\\ disease\\.\ \(0\)\
\-\ this\\ patient\\ has\\ evidence\\ of\\ previous\\ adrenal\\ surgery\\,\\ and\\ has\\ both\\ pancreatic\\ and\\ renal\\ cysts\\.\\ \\ so\\ this\\ is\\ type\\ iib\\.\ \(0\)\
\-\ more\\ than\\ half\\ of\\ these\\ patients\\ will\\ develop\\ or\\ present\\ with\\ retinal\\ angiomas\\.\\ \\ these\\ are\\ actually\\ hemangioblastomas\\ of\\ the\\ retina\\,\\ and\\ cause\\ retinal\\ hemorrhage\\ and\\ detachment\\.\\ \\ two\\-thirds\\ or\\ more\\ of\\ vhl\\ patients\\ will\\ have\\ hemangioblastomas\\,\\ usually\\ infratentorial\\,\\ with\\ the\\ cerebellum\\ by\\ far\\ the\\ most\\ common\\ site\\.\\ \\ although\\ the\\ hemangioblastoma\\ is\\ a\\ benign\\ nonglial\\ neoplasm\\,\\ it\\ is\\ hypervascular\\,\\ and\\ may\\ recur\\ if\\ incompletely\\ resected\\.\\ \\ in\\ addition\\,\\ patients\\ with\\ vhl\\ are\\ prone\\ to\\ develop\\ multiple\\ hemangioblastomas\\,\\ that\\ may\\ be\\ present\\ simultaneously\\ or\\ may\\ appear\\ as\\ metachronous\\ \\(asynchronous\\)\\ lesions\\.\ \(0\)\
\-\ as\\ this\\ patient\\ illustrates\\,\\ the\\ epididymis\\ may\\ develop\\ benign\\ cystadenomas\\.\\ \\ the\\ presence\\ of\\ multiple\\ lesions\\ should\\ always\\ suggest\\ a\\ systemic\\ disease\\.\\ \\ systemic\\ diseases\\ may\\ be\\ congenital\\ \\(maldevelopmental\\ and\\ genetic\\)\\,\\ inflammatory\\ \\(infectious\\,\\ autoimmune\\,\\ etc\\.\\)\\,\\ toxic\\,\\ metabolic\\,\\ and\\ dissemination\\ of\\ a\\ neoplasm\\ \\(metastasis\\)\\.\\ \\ hematogenous\\ dissemination\\ of\\ neoplasms\\ and\\ infection\\ may\\ create\\ multiple\\ and\\ often\\ bilateral\\ lesions\\,\\ but\\ they\\ are\\ usually\\ located\\ in\\ asymmetric\\ and\\ somewhat\\ random\\ patterns\\.\\ \\ however\\,\\ toxic\\,\\ metabolic\\ and\\ genetic\\ lesions\\ may\\ show\\ anatomic\\ distributions\\ of\\ lesions\\ that\\ may\\ be\\ bilateral\\ and\\ can\\ be\\ strikingly\\ symmetric\\.\ \(0\)\
\-\ in\\ the\\ differential\\ diagnosis\\ of\\ this\\ case\\,\\ the\\ presence\\ of\\ bilateral\\ masses\\ of\\ the\\ scrotum\\ could\\ have\\ been\\ inflammatory\\ or\\ infectious\\.\\ \\ however\\,\\ the\\ localization\\ of\\ these\\ masses\\ with\\ anatomic\\ symmetry\\ within\\ the\\ epididymis\\,\\ might\\ suggest\\ consideration\\ of\\ a\\ syndrome\\.\\ \\ in\\ addition\\,\\ the\\ morphology\\ of\\ the\\ masses\\ as\\ heterogeneously\\ solid\\ and\\ cystic\\ also\\ suggests\\ the\\ specific\\ diagnosis\\ of\\ a\\ cystadenoma\\.\\ \\ these\\ two\\ clues\\ fit\\ together\\ well\\ if\\ the\\ patient\\ has\\ von\\ hippel\\-lindau\\ disease\\.\ \(0\)\
\-\ suggested\\ readings\\:\ \(0\)\
\-\ binkovitz\\,\\ l\\.a\\.\\,\\ johnson\\,\\ c\\.d\\.\\,\\ and\\ stephens\\,\\ d\\.h\\.\\ \\"islet\\ cell\\ tumors\\ in\\ von\\ hippel\\-lindau\\ disease\\:\\ increased\\ prevalence\\ and\\ relationship\\ to\\ the\\ multiple\\ endocrine\\ neoplasias\\.\\"\\.\\ ajr\\ 1990\\;155\\:501\\-505\\.\ \(0\)\
\-\ choyke\\,\\ p\\.l\\.\\,\\ glenn\\,\\ g\\.m\\.\\,\\ walther\\,\\ m\\.m\\.\\,\\ zbar\\,\\ b\\.\\,\\ weiss\\,\\ g\\.h\\.\\,\\ alexander\\,\\ r\\.b\\.\\,\\ and\\ hayes\\,\\ w\\.s\\.\\ \\"the\\ natural\\ history\\ of\\ renal\\ lesions\\ in\\ von\\ hippel\\-lindau\\ disease\\:\\ a\\ serial\\ ct\\ study\\ in\\ 28\\ patients\\.\\"\\.\\ ajr\\ 1992\\;159\\:1229\\-1234\\.\ \(0\)\
\-\ choyke\\,\\ p\\.l\\.\\,\\ glenn\\,\\ g\\.m\\.\\,\\ walther\\,\\ m\\.m\\.\\,\\ patronas\\,\\ n\\.j\\.\\,\\ linehan\\,\\ w\\.m\\.\\,\\ and\\ zbar\\,\\ b\\.\\ von\\ hippel\\-lindau\\ disease\\:\\ genetic\\,\\ clinical\\,\\ and\\ imaging\\ features\\.\\ radiology\\ 1995194\\:629\\-642\\.\\ \ \(0\)\
\-\ ho\\,\\ v\\.b\\.\\,\\ smirniotopoulos\\,\\ j\\.g\\.\\,\\ murphy\\,\\ f\\.m\\.\\,\\ and\\ rushing\\,\\ e\\.j\\.\\ radiologic\\-pathologic\\ correlation\\:\\ hemangioblastoma\\.\\ ajnr\\ am\\ j\\ neuroradiol\\ 1992\\;13\\(5\\)\\:1343\\-1352\\.\ \(0\)\
\-\ neumann\\,\\ h\\.\\ basic\\ criteria\\ for\\ clinical\\ diagnosis\\ and\\ genetic\\ counseling\\ in\\ von\\ hippel\\-lindau\\ syndrome\\.\\ vasa\\ 198716\\:220\\-226\ \(0\)\
\-\ tibbs\\ jr\\.\\,\\ r\\.e\\.\\,\\ bowles\\ jr\\.\\,\\ a\\.p\\.\\,\\ raila\\,\\ f\\.a\\.\\,\\ fratkin\\,\\ j\\.d\\.\\,\\ and\\ hutchins\\,\\ j\\.b\\.\\ should\\ endolymphatic\\ sac\\ tumors\\ be\\ considered\\ part\\ of\\ the\\ von\\ hippel\\-lindau\\ complex\\?\\ pathology\\ case\\ report\\.\\ neurosurg\\ 1997\\;40\\(4\\)\\:848\\-855\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vhl\\:\\ 0\\.08416268900013385\ \(0\)\
\-\ von\\:\\ 0\\.06448457888267416\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.0570567269648285\ \(0\)\
\-\ hemangioblastomas\\:\\ 0\\.03237134667907019\ \(0\)\
\-\ systemic\\:\\ 0\\.03117310919039118\ \(0\)\
\-\ epididymal\\:\\ 0\\.029932933659743727\ \(0\)\
\-\ lindau\\:\\ 0\\.026543696873877625\ \(0\)\
\-\ lesions\\:\\ 0\\.02491895976409529\ \(0\)\
\-\ \\,\\:\\ 0\\.024770855668248517\ \(0\)\
\-\ disease\\:\\ 0\\.02434400943295345\ \(0\)\
\-\ cystadenomas\\:\\ 0\\.024278510009302638\ \(0\)\
\-\ mutation\\:\\ 0\\.02373953199991296\ \(0\)\
\-\ iib\\:\\ 0\\.023549282717426137\ \(0\)\
\-\ pancreatic\\:\\ 0\\.02277118429050579\ \(0\)\
\-\ masses\\:\\ 0\\.022026303688423322\ \(0\)\
\-\ chromosome\\:\\ 0\\.020688273771825156\ \(0\)\
\-\ genetic\\:\\ 0\\.020358970359803774\ \(0\)\
\-\ choyke\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ p\\.l\\.\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ glenn\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ g\\.m\\.\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ walther\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ m\\.m\\.\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ zbar\\:\\ 0\\.01920592249230174\ \(0\)\
\-\ gene\\:\\ 0\\.018707437812445042\ \(0\)\
\-\ somatic\\:\\ 0\\.017695797915918417\ \(0\)\
\-\ hippel\\:\\ 0\\.017695797915918417\ \(0\)\
\-\ patients\\:\\ 0\\.016863858600830263\ \(0\)\
\-\ renal\\:\\ 0\\.016780885944170387\ \(0\)\
\-\ may\\:\\ 0\\.01633401628669389\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.016014101594142398\ \(0\)\
\-\ bilateral\\:\\ 0\\.015813424951199462\ \(0\)\
\-\ jr\\.\\:\\ 0\\.015699521811617427\ \(0\)\
\-\ iia\\:\\ 0\\.014675548763151771\ \(0\)\
\-\ cysts\\:\\ 0\\.014585874870724911\ \(0\)\
\-\ these\\:\\ 0\\.014534932627175427\ \(0\)\
\-\ dissemination\\:\\ 0\\.014189397235234102\ \(0\)\
\-\ tumors\\:\\ 0\\.013985692190285408\ \(0\)\
\-\ angiomas\\:\\ 0\\.013981749784680019\ \(0\)\
\-\ develop\\:\\ 0\\.013926933112307052\ \(0\)\
\-\ islet\\:\\ 0\\.01345634225348854\ \(0\)\
\-\ retina\\:\\ 0\\.013306030986632437\ \(0\)\
\-\ epididymis\\:\\ 0\\.013165424186768448\ \(0\)\
\-\ 1992\\:\\ 0\\.01290881626594844\ \(0\)\
\-\ type\\:\\ 0\\.012551739557067149\ \(0\)\
\-\ retinal\\:\\ 0\\.012471625208296694\ \(0\)\
\-\ has\\:\\ 0\\.012236274284814755\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.012025450017346775\ \(0\)\
\-\ \\-\\:\\ 0\\.011972081429466428\ \(0\)\
\-\ ajr\\:\\ 0\\.01186976599995648\ \(0\)\
\-\ prevalence\\:\\ 0\\.011460066149187549\ \(0\)\
\-\ solid\\:\\ 0\\.011138387753288822\ \(0\)\
\-\ b\\.\\:\\ 0\\.01106285142850355\ \(0\)\
\-\ toxic\\:\\ 0\\.010912540161647449\ \(0\)\
\-\ affecting\\:\\ 0\\.010359641423573158\ \(0\)\
\-\ hemangioblastoma\\:\\ 0\\.010285781833865791\ \(0\)\
\-\ \\(\\:\\ 0\\.010229523356394538\ \(0\)\
\-\ presence\\:\\ 0\\.010136554308683429\ \(0\)\
\-\ \\)\\:\\ 0\\.010104564267399745\ \(0\)\
\-\ cell\\:\\ 0\\.010057693732381206\ \(0\)\
\-\ multiple\\:\\ 0\\.009802864942697543\ \(0\)\
\-\ inflammatory\\:\\ 0\\.009684039033307267\ \(0\)\
\-\ benign\\:\\ 0\\.009637419500108501\ \(0\)\
\-\ von\\-hippel\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ germ\\-line\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ germline\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 3p\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 1\\/35\\,000\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 1\\/50\\,000\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ subclassifying\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ asynchronous\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ maldevelopmental\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ binkovitz\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ l\\.a\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ c\\.d\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 155\\:501\\-505\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ g\\.h\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ r\\.b\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ hayes\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ w\\.s\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 159\\:1229\\-1234\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ n\\.j\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ linehan\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 1995194\\:629\\-642\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ v\\.b\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ f\\.m\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ e\\.j\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ \\:1343\\-1352\\.\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ 198716\\:220\\-226\\:\\ 0\\.00960296124615087\ \(0\)\
\-\ pancreas\\:\\ 0\\.009526943719991682\ \(0\)\
\-\ neoplasms\\:\\ 0\\.009476275174971493\ \(0\)\
\-\ suggested\\:\\ 0\\.009476275174971493\ \(0\)\
\-\ adrenal\\:\\ 0\\.009426758288092285\ \(0\)\
\-\ anatomic\\:\\ 0\\.009402415585264126\ \(0\)\
\-\ suggests\\:\\ 0\\.009307676779295195\ \(0\)\
\-\ metabolic\\:\\ 0\\.00919476813471004\ \(0\)\
\-\ nonglial\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ metachronous\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ strikingly\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ readings\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ stephens\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ d\\.h\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ neoplasias\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ patronas\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ w\\.m\\.\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ smirniotopoulos\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ j\\.g\\.\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ rushing\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ neumann\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ tibbs\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ r\\.e\\.\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ bowles\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ raila\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ f\\.a\\.\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ fratkin\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ j\\.d\\.\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ hutchins\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ j\\.b\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ \\:848\\-855\\:\\ 0\\.008847898957959208\ \(0\)\
\-\ \\;\\:\\ 0\\.008825364655566858\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.00853493655553316\ \(0\)\
\-\ racial\\:\\ 0\\.008406215833658377\ \(0\)\
\-\ detachment\\:\\ 0\\.008406215833658377\ \(0\)\
\-\ vasa\\:\\ 0\\.008406215833658377\ \(0\)\
\-\ a\\.p\\.\\:\\ 0\\.008406215833658377\ \(0\)\
\-\ endolymphatic\\:\\ 0\\.008406215833658377\ \(0\)\
\-\ infratentorial\\:\\ 0\\.008092836669767548\ \(0\)\
\-\ johnson\\:\\ 0\\.008092836669767548\ \(0\)\
\-\ weiss\\:\\ 0\\.008092836669767548\ \(0\)\
\-\ alexander\\:\\ 0\\.008092836669767548\ \(0\)\
\-\ infectious\\:\\ 0\\.008004041105585705\ \(0\)\
\-\ syndrome\\:\\ 0\\.007986622799786411\ \(0\)\
\-\ suggest\\:\\ 0\\.007928907824384901\ \(0\)\
\-\ addition\\:\\ 0\\.007892291008880802\ \(0\)\
\-\ features\\:\\ 0\\.00785627945778884\ \(0\)\
\-\ eca\\:\\ 0\\.007849760905808714\ \(0\)\
\-\ phakomatoses\\:\\ 0\\.007849760905808714\ \(0\)\
\-\ simultaneously\\:\\ 0\\.007849760905808714\ \(0\)\
\-\ however\\:\\ 0\\.007775712599990427\ \(0\)\
\-\ clues\\:\\ 0\\.007651153545466714\ \(0\)\
\-\ radiologic\\-pathologic\\:\\ 0\\.007483233414935932\ \(0\)\
\-\ neuroradiol\\:\\ 0\\.007483233414935932\ \(0\)\
\-\ complex\\:\\ 0\\.007455099951229057\ \(0\)\
\-\ distributions\\:\\ 0\\.0073377743815758855\ \(0\)\
\-\ symmetry\\:\\ 0\\.0073377743815758855\ \(0\)\
\-\ ajnr\\:\\ 0\\.0073377743815758855\ \(0\)\
\-\ previous\\:\\ 0\\.007229521130007182\ \(0\)\
\-\ be\\:\\ 0\\.007177324201219658\ \(0\)\
\-\ classic\\:\\ 0\\.007133452895006694\ \(0\)\
\-\ both\\:\\ 0\\.007131372518582096\ \(0\)\
\-\ sexual\\:\\ 0\\.007094698617617051\ \(0\)\
\-\ nih\\:\\ 0\\.007094698617617051\ \(0\)\
\-\ as\\:\\ 0\\.007040182493976731\ \(0\)\
\-\ ho\\:\\ 0\\.006990874892340009\ \(0\)\
\-\ more\\:\\ 0\\.00698423630494172\ \(0\)\
\-\ two\\-thirds\\:\\ 0\\.006896091257275053\ \(0\)\
\-\ random\\:\\ 0\\.006896091257275053\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.006845741082342061\ \(0\)\
\-\ neurosurg\\:\\ 0\\.00680889876525595\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.006731207522817788\ \(0\)\
\-\ incompletely\\:\\ 0\\.00672817112674427\ \(0\)\
\-\ and\\:\\ 0\\.006667000212304387\ \(0\)\
\-\ fit\\:\\ 0\\.006653015493316219\ \(0\)\
\-\ create\\:\\ 0\\.006582712093384224\ \(0\)\
\-\ counseling\\:\\ 0\\.006582712093384224\ \(0\)\
\-\ without\\:\\ 0\\.00657520642600706\ \(0\)\
\-\ kidney\\:\\ 0\\.006558569618845338\ \(0\)\
\-\ that\\:\\ 0\\.006431288577598359\ \(0\)\
\-\ in\\:\\ 0\\.006426537278827417\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0064124814731386275\ \(0\)\
\-\ are\\:\\ 0\\.006344628935346415\ \(0\)\
\-\ neoplasm\\:\\ 0\\.006340210405036881\ \(0\)\
\-\ subtypes\\:\\ 0\\.006286488002443438\ \(0\)\
\-\ rcc\\:\\ 0\\.006286488002443438\ \(0\)\
\-\ recur\\:\\ 0\\.006286488002443438\ \(0\)\
\-\ it\\:\\ 0\\.00627728230239548\ \(0\)\
\-\ 1990\\:\\ 0\\.006235812604148347\ \(0\)\
\-\ people\\:\\ 0\\.0061873902048337134\ \(0\)\
\-\ natural\\:\\ 0\\.0061873902048337134\ \(0\)\
\-\ \\:\\:\\ 0\\.006156180914981836\ \(0\)\
\-\ predilection\\:\\ 0\\.0061410289690833906\ \(0\)\
\-\ study\\:\\ 0\\.006125558511677472\ \(0\)\
\-\ is\\:\\ 0\\.006125171877829256\ \(0\)\
\-\ responsible\\:\\ 0\\.006053836477064288\ \(0\)\
\-\ localization\\:\\ 0\\.006053836477064288\ \(0\)\
\-\ have\\:\\ 0\\.006047183262631019\ \(0\)\
\-\ sporadic\\:\\ 0\\.0060127250086733875\ \(0\)\
\-\ hematogenous\\:\\ 0\\.0060127250086733875\ \(0\)\
\-\ together\\:\\ 0\\.005973108838552609\ \(0\)\
\-\ h\\.\\:\\ 0\\.005973108838552609\ \(0\)\
\-\ should\\:\\ 0\\.005935094862502833\ \(0\)\
\-\ autoimmune\\:\\ 0\\.00593488299997824\ \(0\)\
\-\ patterns\\:\\ 0\\.00593488299997824\ \(0\)\
\-\ basic\\:\\ 0\\.00593488299997824\ \(0\)\
\-\ further\\:\\ 0\\.0059203576074079705\ \(0\)\
\-\ unlike\\:\\ 0\\.005862234443879469\ \(0\)\
\-\ divided\\:\\ 0\\.005862234443879469\ \(0\)\
\-\ will\\:\\ 0\\.005824577382089634\ \(0\)\
\-\ recognized\\:\\ 0\\.0057941294798475144\ \(0\)\
\-\ scrotum\\:\\ 0\\.0057941294798475144\ \(0\)\
\-\ murphy\\:\\ 0\\.0057941294798475144\ \(0\)\
\-\ endocrine\\:\\ 0\\.005761609912146337\ \(0\)\
\-\ united\\:\\ 0\\.0057300330745937746\ \(0\)\
\-\ actually\\:\\ 0\\.0057300330745937746\ \(0\)\
\-\ clinical\\:\\ 0\\.005728343790993474\ \(0\)\
\-\ the\\:\\ 0\\.005722737275313486\ \(0\)\
\-\ familial\\:\\ 0\\.005699345844782559\ \(0\)\
\-\ usually\\:\\ 0\\.005653438461583353\ \(0\)\
\-\ illustrates\\:\\ 0\\.00564044908958618\ \(0\)\
\-\ prone\\:\\ 0\\.0055845740412337275\ \(0\)\
\-\ morphology\\:\\ 0\\.005557675770438117\ \(0\)\
\-\ relationship\\:\\ 0\\.005531425714251775\ \(0\)\
\-\ scrotal\\:\\ 0\\.005505793364131739\ \(0\)\
\-\ hypervascular\\:\\ 0\\.005505793364131739\ \(0\)\
\-\ heterogeneously\\:\\ 0\\.005480750315956686\ \(0\)\
\-\ or\\:\\ 0\\.005454916933353527\ \(0\)\
\-\ cutaneous\\:\\ 0\\.00540890067783926\ \(0\)\
\-\ cystadenoma\\:\\ 0\\.00540890067783926\ \(0\)\
\-\ autosomal\\:\\ 0\\.00538596668089173\ \(0\)\
\-\ estimated\\:\\ 0\\.00538596668089173\ \(0\)\
\-\ cystic\\:\\ 0\\.0053695701683044855\ \(0\)\
\-\ organs\\:\\ 0\\.005341498277274894\ \(0\)\
\-\ shortly\\:\\ 0\\.005298774188872626\ \(0\)\
\-\ might\\:\\ 0\\.005278024521148559\ \(0\)\
\-\ originally\\:\\ 0\\.005257662720481726\ \(0\)\
\-\ far\\:\\ 0\\.005257662720481726\ \(0\)\
\-\ provide\\:\\ 0\\.0052180465503609465\ \(0\)\
\-\ 1997\\:\\ 0\\.0052180465503609465\ \(0\)\
\-\ consideration\\:\\ 0\\.005198765965285347\ \(0\)\
\-\ a\\:\\ 0\\.005184311134883677\ \(0\)\
\-\ correlation\\:\\ 0\\.005124885141386914\ \(0\)\
\-\ criteria\\:\\ 0\\.0050897425899509435\ \(0\)\
\-\ been\\:\\ 0\\.00506491261321131\ \(0\)\
\-\ if\\:\\ 0\\.005051728613901167\ \(0\)\
\-\ etc\\:\\ 0\\.005039067191655853\ \(0\)\
\-\ every\\:\\ 0\\.004944283556590897\ \(0\)\
\-\ half\\:\\ 0\\.004914437179479661\ \(0\)\
\-\ 31\\:\\ 0\\.004885386801394518\ \(0\)\
\-\ evidence\\:\\ 0\\.004881138525853764\ \(0\)\
\-\ than\\:\\ 0\\.00487810208043197\ \(0\)\
\-\ developing\\:\\ 0\\.00487114706112507\ \(0\)\
\-\ group\\:\\ 0\\.004843214130173723\ \(0\)\
\-\ always\\:\\ 0\\.004789409385805992\ \(0\)\
\-\ am\\:\\ 0\\.004789409385805992\ \(0\)\
\-\ neoplastic\\:\\ 0\\.004763471859995841\ \(0\)\
\-\ dominant\\:\\ 0\\.0047507310759400765\ \(0\)\
\-\ diseases\\:\\ 0\\.004689170934041012\ \(0\)\
\-\ frequent\\:\\ 0\\.004653838389647598\ \(0\)\
\-\ serial\\:\\ 0\\.004642311037435684\ \(0\)\
\-\ pmh\\:\\ 0\\.004630904392700069\ \(0\)\
\-\ cerebellum\\:\\ 0\\.004630904392700069\ \(0\)\
\-\ resected\\:\\ 0\\.004608443295529331\ \(0\)\
\-\ somewhat\\:\\ 0\\.004575596848720304\ \(0\)\
\-\ uncommon\\:\\ 0\\.0045542368581011575\ \(0\)\
\-\ association\\:\\ 0\\.004522962232956897\ \(0\)\
\-\ asymmetric\\:\\ 0\\.004522962232956897\ \(0\)\
\-\ sac\\:\\ 0\\.004512733757630274\ \(0\)\
\-\ part\\:\\ 0\\.004512733757630274\ \(0\)\
\-\ into\\:\\ 0\\.004429904941088686\ \(0\)\
\-\ rather\\:\\ 0\\.004424758423594918\ \(0\)\
\-\ associated\\:\\ 0\\.0043931646228925975\ \(0\)\
\-\ 28\\:\\ 0\\.004387828628741234\ \(0\)\
\-\ states\\:\\ 0\\.004378788538529147\ \(0\)\
\-\ 3\\:\\ 0\\.004359423805460871\ \(0\)\
\-\ most\\:\\ 0\\.004298115777185352\ \(0\)\
\-\ local\\:\\ 0\\.0042757835465629035\ \(0\)\
\-\ symmetric\\:\\ 0\\.004251485335763014\ \(0\)\
\-\ so\\:\\ 0\\.004235582504149558\ \(0\)\
\-\ present\\:\\ 0\\.004204812100069022\ \(0\)\
\-\ j\\:\\ 0\\.004204456826105924\ \(0\)\
\-\ 13\\:\\ 0\\.004204456826105924\ \(0\)\
\-\ this\\:\\ 0\\.0041879617137870724\ \(0\)\
\-\ report\\:\\ 0\\.0041667601712284995\ \(0\)\
\-\ even\\:\\ 0\\.004144752864782399\ \(0\)\
\-\ case\\:\\ 0\\.0040729944071182375\ \(0\)\
\-\ ii\\:\\ 0\\.0040148362843610294\ \(0\)\
\-\ described\\:\\ 0\\.003964453912192451\ \(0\)\
\-\ findings\\:\\ 0\\.0039626077032461\ \(0\)\
\-\ site\\:\\ 0\\.00393410864584935\ \(0\)\
\-\ radiology\\:\\ 0\\.00393410864584935\ \(0\)\
\-\ 40\\:\\ 0\\.003916299127329165\ \(0\)\
\-\ i\\:\\ 0\\.0038478373586367212\ \(0\)\
\-\ specific\\:\\ 0\\.0038478373586367212\ \(0\)\
\-\ located\\:\\ 0\\.003831373700891571\ \(0\)\
\-\ appear\\:\\ 0\\.003809802211462181\ \(0\)\
\-\ pathology\\:\\ 0\\.003809802211462181\ \(0\)\
\-\ considered\\:\\ 0\\.003757671469438613\ \(0\)\
\-\ additional\\:\\ 0\\.003732512738725488\ \(0\)\
\-\ patient\\:\\ 0\\.0037324267142326275\ \(0\)\
\-\ vs\\:\\ 0\\.003665010861003048\ \(0\)\
\-\ \\?\\:\\ 0\\.003632766340549572\ \(0\)\
\-\ about\\:\\ 0\\.0035882979369327365\ \(0\)\
\-\ course\\:\\ 0\\.003512561485245797\ \(0\)\
\-\ metastasis\\:\\ 0\\.003484474211655694\ \(0\)\
\-\ could\\:\\ 0\\.0034341589802075736\ \(0\)\
\-\ congenital\\:\\ 0\\.0034043126030963377\ \(0\)\
\-\ risk\\:\\ 0\\.003371684801044757\ \(0\)\
\-\ malignant\\:\\ 0\\.00336456500694913\ \(0\)\
\-\ they\\:\\ 0\\.00335397181534565\ \(0\)\
\-\ identified\\:\\ 0\\.003326216820464403\ \(0\)\
\-\ of\\:\\ 0\\.003299671918025816\ \(0\)\
\-\ typically\\:\\ 0\\.0032858668513136955\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0031850481613733416\ \(0\)\
\-\ cause\\:\\ 0\\.0031495235583354755\ \(0\)\
\-\ although\\:\\ 0\\.0031437138132642743\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.0030983187191460084\ \(0\)\
\-\ vascular\\:\\ 0\\.0030520732766053343\ \(0\)\
\-\ body\\:\\ 0\\.003023163085717957\ \(0\)\
\-\ often\\:\\ 0\\.002970014758736005\ \(0\)\
\-\ differential\\:\\ 0\\.0029552939317570043\ \(0\)\
\-\ resection\\:\\ 0\\.002902958230414182\ \(0\)\
\-\ show\\:\\ 0\\.0028574683382261725\ \(0\)\
\-\ 5\\:\\ 0\\.0027234862989587837\ \(0\)\
\-\ infection\\:\\ 0\\.002705900407486718\ \(0\)\
\-\ y\\.o\\:\\ 0\\.002686687835061765\ \(0\)\
\-\ two\\:\\ 0\\.002665938167337697\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0026382654357471314\ \(0\)\
\-\ 4\\:\\ 0\\.0025936513128312043\ \(0\)\
\-\ high\\:\\ 0\\.0025474357963799735\ \(0\)\
\-\ at\\:\\ 0\\.0025223598100907038\ \(0\)\
\-\ common\\:\\ 0\\.0024360209280570775\ \(0\)\
\-\ abdominal\\:\\ 0\\.00232670940971908\ \(0\)\
\-\ increased\\:\\ 0\\.002277216537908122\ \(0\)\
\-\ surgery\\:\\ 0\\.002260347564662609\ \(0\)\
\-\ man\\:\\ 0\\.0022014508094662304\ \(0\)\
\-\ imaging\\:\\ 0\\.0021809083055071925\ \(0\)\
\-\ tumor\\:\\ 0\\.002170187692386505\ \(0\)\
\-\ was\\:\\ 0\\.0021531100701823245\ \(0\)\
\-\ can\\:\\ 0\\.0021113533251297056\ \(0\)\
\-\ well\\:\\ 0\\.002105752672079141\ \(0\)\
\-\ \\'s\\:\\ 0\\.002052338364234254\ \(0\)\
\-\ had\\:\\ 0\\.0020085510013515342\ \(0\)\
\-\ but\\:\\ 0\\.0019852977135441587\ \(0\)\
\-\ also\\:\\ 0\\.001835097596590579\ \(0\)\
\-\ \\.\\:\\ 0\\.00181751437535433\ \(0\)\
\-\ within\\:\\ 0\\.0017757422749303724\ \(0\)\
\-\ for\\:\\ 0\\.0015884709120756323\ \(0\)\
\-\ on\\:\\ 0\\.0015771046021033294\ \(0\)\
\-\ by\\:\\ 0\\.0015499683041883168\ \(0\)\
\-\ with\\:\\ 0\\.001402010824606522\ \(0\)\
\-\ to\\:\\ 0\\.0013956474132123735\ \(0\)\
\-\ there\\:\\ 0\\.0013853110636873516\ \(0\)\
\-\ not\\:\\ 0\\.0013451183788038513\ \(0\)\
\-\ ct\\:\\ 0\\.0013020736965054934\ \(0\)\
\-\ history\\:\\ 0\\.0012856367513149058\ \(0\)\
